Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free FENC Stock Alerts

Adherex Technologies (FENC) Competitors

Adherex Technologies logo
$11.88 -0.18 (-1.53%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

FENC vs. HROW, PAHC, AVLN, XERS, and LBRX

Should you buy Adherex Technologies stock or one of its competitors? Adherex Technologies's main competitors and comparable companies include Harrow (HROW), Phibro Animal Health (PAHC), Avalyn Pharma (AVLN), Xeris Biopharma (XERS), and LB Pharmaceuticals (LBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adherex Technologies compare to Harrow?

Harrow (NASDAQ:HROW) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Adherex Technologies has a net margin of -6.09% compared to Harrow's net margin of -13.51%. Adherex Technologies' return on equity of -6.93% beat Harrow's return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-13.51% -31.83% -3.42%
Adherex Technologies -6.09%-6.93%-2.48%

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 73.04%. Adherex Technologies has a consensus target price of $16.40, indicating a potential upside of 38.09%. Given Harrow's higher probable upside, equities analysts clearly believe Harrow is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
2 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.55
Adherex Technologies
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Harrow has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M5.52-$5.14M-$1.00N/A
Adherex Technologies$44.64M9.33-$9.74M-$0.29N/A

In the previous week, Harrow had 19 more articles in the media than Adherex Technologies. MarketBeat recorded 29 mentions for Harrow and 10 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.67 beat Harrow's score of 0.36 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harrow
7 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adherex Technologies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

72.8% of Harrow shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

Harrow and Adherex Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Phibro Animal Health?

Adherex Technologies (NASDAQ:FENC) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Phibro Animal Health has a net margin of 6.35% compared to Adherex Technologies' net margin of -6.09%. Phibro Animal Health's return on equity of 37.14% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies-6.09% -6.93% -2.48%
Phibro Animal Health 6.35%37.14%8.57%

Adherex Technologies presently has a consensus price target of $16.40, indicating a potential upside of 38.09%. Phibro Animal Health has a consensus price target of $42.50, indicating a potential upside of 23.60%. Given Adherex Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Adherex Technologies is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Phibro Animal Health
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Adherex Technologies had 8 more articles in the media than Phibro Animal Health. MarketBeat recorded 10 mentions for Adherex Technologies and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.18 beat Adherex Technologies' score of 0.67 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adherex Technologies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Phibro Animal Health
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Phibro Animal Health has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$44.64M9.33-$9.74M-$0.29N/A
Phibro Animal Health$1.50B0.93$48.26M$2.3314.76

Adherex Technologies has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Phibro Animal Health beats Adherex Technologies on 10 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Avalyn Pharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Avalyn Pharma's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Avalyn PharmaN/A N/A N/A
Adherex Technologies -6.09%-6.93%-2.48%

55.5% of Adherex Technologies shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Adherex Technologies had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 10 mentions for Adherex Technologies and 9 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.72 beat Adherex Technologies' score of 0.67 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avalyn Pharma
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adherex Technologies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Avalyn Pharma currently has a consensus price target of $60.00, indicating a potential upside of 54.48%. Adherex Technologies has a consensus price target of $16.40, indicating a potential upside of 38.09%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalyn Pharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.20
Adherex Technologies
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Avalyn Pharma has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalyn PharmaN/AN/AN/A-$21.83N/A
Adherex Technologies$44.64M9.33-$9.74M-$0.29N/A

Summary

Avalyn Pharma beats Adherex Technologies on 8 of the 14 factors compared between the two stocks.

How does Adherex Technologies compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Xeris Biopharma has a net margin of -5.12% compared to Adherex Technologies' net margin of -6.09%. Xeris Biopharma's return on equity of 158.10% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-5.12% 158.10% 3.57%
Adherex Technologies -6.09%-6.93%-2.48%

In the previous week, Xeris Biopharma had 13 more articles in the media than Adherex Technologies. MarketBeat recorded 23 mentions for Xeris Biopharma and 10 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.67 beat Xeris Biopharma's score of 0.15 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adherex Technologies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 25.95%. Adherex Technologies has a consensus target price of $16.40, indicating a potential upside of 38.09%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Adherex Technologies
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Xeris Biopharma has higher revenue and earnings than Adherex Technologies. Xeris Biopharma is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$291.85M5.36$550K-$0.11N/A
Adherex Technologies$44.64M9.33-$9.74M-$0.29N/A

Xeris Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Xeris Biopharma and Adherex Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Adherex Technologies has higher revenue and earnings than LB Pharmaceuticals. Adherex Technologies is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LB PharmaceuticalsN/AN/A-$25.20M-$1.73N/A
Adherex Technologies$44.64M9.33-$9.74M-$0.29N/A

55.5% of Adherex Technologies shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LB Pharmaceuticals has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -6.93% beat LB Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
LB PharmaceuticalsN/A -25.96% -25.03%
Adherex Technologies -6.09%-6.93%-2.48%

LB Pharmaceuticals presently has a consensus price target of $47.75, suggesting a potential upside of 2.93%. Adherex Technologies has a consensus price target of $16.40, suggesting a potential upside of 38.09%. Given Adherex Technologies' higher possible upside, analysts plainly believe Adherex Technologies is more favorable than LB Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LB Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Adherex Technologies
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, LB Pharmaceuticals and LB Pharmaceuticals both had 10 articles in the media. Adherex Technologies' average media sentiment score of 0.67 beat LB Pharmaceuticals' score of 0.43 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LB Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adherex Technologies
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Adherex Technologies beats LB Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FENC vs. The Competition

Export
MetricAdherex TechnologiesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$416.93M$11.73B$6.98B$13.02B
Dividend YieldN/A2.70%2.58%10.72%
P/E Ratio-91.48781.45269.2725.24
Price / Sales9.33748.18597.12100.97
Price / CashN/A67.4570.5350.75
Price / Book11.4210.7313.066.33
Net Income-$9.74M$2.77B$3.45B$347.70M
7 Day Performance2.64%-0.11%0.91%0.94%
1 Month Performance6.42%0.06%1.59%0.90%
1 Year Performance39.23%161.21%67.34%20.38%

Adherex Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FENC
Adherex Technologies
3.9169 of 5 stars		$11.88
-1.5%		$16.40
+38.1%		+32.4%$416.93M$44.64MN/A10
HROW
Harrow
4.0613 of 5 stars		$39.92
+1.3%		$69.43
+73.9%		+6.5%$1.47B$272.30MN/A180
PAHC
Phibro Animal Health
4.7172 of 5 stars		$35.50
-1.4%		$42.50
+19.7%		+10.0%$1.46B$1.30B15.242,475
AVLN
Avalyn Pharma
4.3411 of 5 stars		$32.70
+2.2%		$59.00
+80.4%		N/A$1.42BN/AN/A51
XERS
Xeris Biopharma
3.4763 of 5 stars		$7.36
-9.2%		$10.80
+46.7%		+14.5%$1.40B$291.85M122.67290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Why November 27 Is Quickly Becoming America's Most Important Financial Date in Decades
An estimated $10 trillion could move through a little known government initiative, according to analyst Joel L...
Altimetry | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel